J&J In Deal With Catalyst Biosciences To Discover Inflammatory Disease Candidates
This article was originally published in The Pink Sheet Daily
Executive Summary
South San Francisco protease engineering firm also plans to enter the clinic in 2009 with an internally developed competitor to Novo Nordisk’s hemophilia drug NovoSeven, Catalyst CEO Usman tells “The Pink Sheet” DAILY.
You may also be interested in...
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Alzheimer’s, BRAIN Initiative Highlighted In $30 Billion NIH Budget Proposal
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: